This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot) (RASUNOA)

This study has been completed.
Information provided by (Responsible Party):
Prof. Roland Veltkamp, University Hospital Heidelberg Identifier:
First received: May 7, 2013
Last updated: August 15, 2015
Last verified: August 2015
The registry of acute stroke under new oral anticoagulants (RASUNOA) is a German multicenter, prospective, observational registry performed at about 50 study centers covering about 50.000 acute ischemic strokes and 6000 acute intracranial hemorrhages per year. Study enrollment will be consecutive. The RASUNOA registry study center is the University Medical Center of the Principal Investigator (Heidelberg, Germany). The registry will focus on treatment decisions and concepts in patients being under treatment with a new oral anticoagulant and suffering from acute ischemic or hemorrhagic stroke.

Ischemic Stroke Intracranial Hemorrhage

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)

Resource links provided by NLM:

Further study details as provided by Prof. Roland Veltkamp, University Hospital Heidelberg:

Primary Outcome Measures:
  • Rate of hematoma expansion (ICH) [ Time Frame: 48h after ICH ]
    Rate of hematoma enlargement in patients with ICH between initial imaging and follow-up imaging (CT)

  • Symptomatic intracerebral haemorrhage after thrombolysis [ Time Frame: 24 h ]
    In patients with ischemic stroke while under treatment with any of the new OAC who receive thrombolysis we will measure any hemorrhagic transformation on routine follow-up CT imaging (usually within 24h after thrombolysis)

Enrollment: 353
Study Start Date: January 2012
Study Completion Date: August 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.

Detailed Description:
The main purpose of the study is to collect information from a large, prospectively enrolling multicentre stroke database regarding the optimal management of ischemic and hemorrhagic stroke during anticoagulation with nOAC. Specifically, we aim to obtain critical information regarding the epidemiology, natural history, laboratory and neuroradiological aspects, clinical consequences, and the effects of treatment (i.e. thrombolysis/interventional recanalisation in ischemic stroke and hemostatic therapy in ICH, respectively) in stroke during nOAC. The Registry is not limited to a specific new OAC but intends to examine stroke during use of any of the approved nOAC. The study is not designed to perform comparisons among the different nOAC.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients suffering from acute ischemic stroke or intracranial hemorrhage while being anti coagulated. Only patients taking new oral anticoagulants will be included.

Inclusion Criteria:

  • age >= 18 years
  • informed consent
  • acute stroke or intracranial bleeding
  • therapy with a new oral anticoagulant (Dabigatran®, Rivaroxaban®, Apixaban®, Edoxaban®)

Exclusion Criteria:

  • missing informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01850797

University Hospital Heidelberg
Heidelberg, Germany, 69120
Sponsors and Collaborators
University Hospital Heidelberg
Principal Investigator: Roland Veltkamp, Prof. University Hospital Heidelberg
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Roland Veltkamp, Senior Physician, Department of Neurology, University Hospital Heidelberg, University Hospital Heidelberg Identifier: NCT01850797     History of Changes
Other Study ID Numbers: S-556/2011
Study First Received: May 7, 2013
Last Updated: August 15, 2015

Keywords provided by Prof. Roland Veltkamp, University Hospital Heidelberg:
oral anticoagulants
ischemic stroke
blood thinner
intracranial hemorrhage

Additional relevant MeSH terms:
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Anticoagulants processed this record on September 20, 2017